B. Powell

发表

Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer.

B. Iacopetta, B. Powell, R. Soong, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma. Influence of tumour site, stage, adjuvant chemotherapy and type of mutation.

B. Iacopetta, B. Powell, R. Soong, 2000, European journal of cancer.

P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma.

B. Iacopetta, B. Powell, H. Elsaleh, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Can p53 alterations be used to predict tumour response to pre-operative chemo-radiotherapy in locally advanced rectal cancer?

B. Iacopetta, B. Powell, H. Elsaleh, 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

P 53 Alteration and Microsatellite Instability Have Predictive Value for Survival Benefit from Chemotherapy in Stage III Colorectal Carcinoma 1

B. Iacopetta, B. Powell, H. Elsaleh, 2001 .

p53 Gene Mutation, Microsatellite Instability and Adjuvant Chemotherapy: Impact on Survival of 388 Patients with Dukes’ C Colon Carcinoma

B. Iacopetta, B. Powell, H. Elsaleh, 2000, Oncology.

Associations between common polymorphisms in TP53 and p21WAF1/Cip1 and phenotypic features of breast cancer.

E. Berns, B. Iacopetta, B. Powell, 2002, Carcinogenesis.

Luteinizing hormone signaling and breast cancer: polymorphisms and age of onset.

E. Berns, B. Iacopetta, B. Powell, 2003, The Journal of clinical endocrinology and metabolism.

Analysis of p53 gene mutation by polymerase chain reaction-single strand conformation polymorphism provides independent prognostic information in node-negative breast cancer.

B. Iacopetta, B. Powell, R. Soong, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Methylenetetrahydrofolate reductase and thymidylate synthase polymorphisms are not associated with breast cancer risk or phenotype.

J. Beilby, B. Iacopetta, B. Powell, 2004, Anticancer research.

Prognostic value of TP53 gene mutation in adjuvant treated breast cancer patients

E. Berns, B. Iacopetta, B. Powell, 2001, Breast Cancer Research and Treatment.

p53 protein overexpression is a prognostic indicator of poor survival in stage I endometrial carcinoma.

B. Iacopetta, B. Powell, R. Soong, 1999, International Journal of Oncology.